Current Report Filing (8-k)
May 01 2019 - 07:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 1, 2019
Checkpoint Therapeutics, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
|
001-38128
(Commission File Number)
|
|
47-2568632
(IRS Employer Identification No.)
|
2 Gansevoort Street, 9
th
Floor
New York, NY 10014
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act.
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2b
under the Exchange Act.
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act.
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 8.01. Other Events.
On May 1, 2019, Checkpoint Therapeutics, Inc. issued a press
release announcing interim clinical results from its ongoing multicenter Phase 1 clinical trial of anti-PD-L1 antibody cosibelimab
(formerly referred to as CK-301). A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 1, 2019
|
Checkpoint Therapeutics,
Inc.
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By
|
|
/s/
James F. Oliviero
|
|
|
|
James F. Oliviero
|
|
|
|
President and Chief Executive
Officer
|
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Mar 2023 to Mar 2024